Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (GLY2)
Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients.
Sponsor: Chiesi Farmaceutici S.p.A.
This PHASE1/PHASE2 trial investigates Chronic Obstructive Pulmonary Disease (COPD) and is currently completed. Chiesi Farmaceutici S.p.A. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2020 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chiesi Farmaceutici S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .